{
  "docId": "019de514-833c-7520-a4a9-200b68fbb681",
  "docSlug": "d869e39fe11534a9d64784c9e4f475f2",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 47 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 47,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-833c-7520-a4a9-200b68fbb681/20",
  "deckHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681",
  "deckJsonHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681.json",
  "deckAnchorHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.23,
        "w": 0.23,
        "x": 0.099,
        "y": 0.201
      },
      "kind": "diagram",
      "text": "PDUFA Date June 2023",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f6777dd-719c-489b-abf9-6bfe7ed00b2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.18,
        "x": 0.779,
        "y": 0.03
      },
      "kind": "image",
      "text": "2023 LAUNCH7",
      "attrs": {},
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48bdc901-e516-4920-b18b-e1d23305bacf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.105,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "image",
      "text": "BAUSCH+LOMB",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68e2b69e-0200-4447-b23f-49ca834c66b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.37,
        "x": 0.088,
        "y": 0.706
      },
      "kind": "list",
      "text": "DED is one of the most common ocular surface disorders, with approximately 18M Americans diagnosed with DED. 2,3",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "140add62-252a-4982-8ac8-ac6f41de45b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.046,
        "w": 0.559,
        "x": 0.389,
        "y": 0.245
      },
      "kind": "list",
      "text": "Investigational first in class treatment for Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d482ffe-49fc-4c22-8aa0-7c437e4183a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.069,
        "w": 0.559,
        "x": 0.389,
        "y": 0.33
      },
      "kind": "list",
      "text": "Consistent statistically significant efficacy, safety and tolerability have now been demonstrated in two Phase 3 studies of NOV031 and one Phase 2 study",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bbfd589-8590-45e7-a00e-616f7338e5c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.046,
        "w": 0.559,
        "x": 0.389,
        "y": 0.415
      },
      "kind": "list",
      "text": "Statistically significant difference of sign and symptom was noted at day 15 and 57 in both Phase 3 studies",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae01bb35-635c-48e3-b838-8aed075ec792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.37,
        "x": 0.088,
        "y": 0.77
      },
      "kind": "list",
      "text": "In one study, it was found that ~90% of patients with DED had MGD involvement.4",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b227ca7f-1911-452d-9857-99a2579e0331",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.11,
        "x": 0.79,
        "y": 0.73
      },
      "kind": "metric",
      "text": "Expect Double Digit Growth 2021-20276,7",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fe716f8-5889-45e7-824d-480cecf371b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.104,
        "x": 0.624,
        "y": 0.73
      },
      "kind": "metric",
      "text": "~24% CAGR 2016-20215",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd68db69-4205-4223-8dcf-67382bd47802",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.61,
        "x": 0.158,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n2. Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy and Dry Eye Disease. Ocular immunology and inflammation, 29(6), 1168-1176. https://doi.org/10.1080/09273948.2020.1841804.\n3. 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope. Retrieved from https://www.market-scope.com/pages/reports/250/2020-ophthalmic-landscape-report-global-analysis-for-2019-to-2025-april-2021#reports.\n4. Badian RA. Sci Rep. 2021;11:23412.; Lemp MA, et al. Cornea. 2012:31:472-478.; Messmer EM. Dtsch Arztebl Int. 2015;112(5):71-81.\n5. IQVIA NSP.\n6. Clarivate\n7. See Slide 1 for further information on forward-looking statements.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56af25a4-db5f-4eea-bb01-53bdf9a80066",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.44,
        "x": 0.046,
        "y": 0.08
      },
      "kind": "title",
      "text": "NOV031: FDA Accepted NDA",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8ceb413-1622-4470-8e6e-7fcc1fbcf8b7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 16,
      "beatId": "3551c60e-c8e3-45ed-affc-e45af107916b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The deck outlines upcoming catalysts, strengthening key consumer franchises, and R&D opportunities.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}